Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. (2nd November 2018)

• Record Type: Journal Article
• Authors: Hattinger, Claudia Maria; Patrizio, Maria Pia; Tavanti, Elisa; Luppi, Silvia; Magagnoli, Federica; Picci, Piero; Serra, Massimo
• Is Part Of: Expert review of molecular diagnostics. Volume 18:Number 11(2018)
• Page Start: 947
• Page End: 961
• Publication Date: 2018-11-02
• Subjects: Genetic biomarkers -- osteosarcoma -- prognosis -- tailored treatments -- toxicity; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2018.1535903
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Introduction : Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered : This review provides an overview of the state of art in genetic testing applied to osteosarcoma, with particular regard to novel candidate genetic biomarkers that can be analyzed in tumor tissue and blood samples, which might be used to predict toxicity and prognosis, detect disease relapse, and improve patients' selection criteria for tailoring treatment. Expert commentary : Genetic testing based on modern technologies is expected to indicate new osteosarcoma-related prognostic markers and driver genes, which may highlight novel therapeutic targets and patients stratification biomarkers. The definition of tailored or targeted treatment approaches may improve outcome of patients with localized tumors and, even more, of those with metastatic disease, for whom progress in cure probability is highly warranted.